Short-term interval combined chemoembolization and radiofrequency ablation for hepatocellular carcinoma

Table 2 Sequential changes of laboratory parameters from the baseline levels to the levels at 1, 3, 6, 12 mo after combination therapy

	Pre-TACE+RFA	After TACE+RFA
Liver function parameters	Baseline	At 1 mo	At 3 mo	At 6 mo	At 9 mo	At 12 mo
ALT (IU/L)	44.41 ± 40.48	51.52 ± 46.19	38.71 ± 28.16	38.50 ± 23.88	38.05 ± 27.72	37.69 ± 20.94
Albumin (g/dL)	3.65 ± 0.52	3.50 ± 0.511	3.64 ± 0.50	3.69 ± 0.48	3.67 ± 0.50	3.66 ± 0.48
Bilirubin (mg/dL)	1.17 ± 0.69	1.23 ± 0.80	1.20 ± 0.69	1.22 ± 0.76	1.23 ± 0.73	1.23 ± 0.79
Prothrombin time (INR)	1.21 ± 0.16	1.22 ± 0.19	1.20 ± 0.17	1.20 ± 0.17	1.20 ± 0.18	1.20 ± 0.19

¹Variables were significantly changed from the baseline levels by paired t-test with Bonferroni correction (^bP < 0.01 vs control). ALT: Alanine aminotransferase; INR: International normalized ratio; RFA: Radiofrequency ablation; TACE: Transcatheter arterial chemoembolization.